Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Effects of smoking on the pharmacokinetics of erlotinibMarta Hamilton, Julie L Wolf, Jason Rusk, et al.Breast Cancer Research and Treatment|November 4, 2005
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancerSyed K Mohsin, D Craig Allred, C Kent Osborne, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2022
Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled TrialVincent S Paramanandam, Elizabeth Dylke, Gary M Clark, et al.Cancer Research|May 17, 2003
Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parametersSuzanne A W Fuqua, Rachel Schiff, Irma Parra, et al.Breast Cancer Research and Treatment|October 26, 2005
Breast tumors that overexpress nuclear metastasis-associated 1 (MTA1) protein have high recurrence risks but enhanced responses to systemic therapiesMichelle D Martin, Susan G Hilsenbeck, Syed K Mohsin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2004
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancerRomán Pérez-Soler, Abraham Chachoua, Lisa A Hammond, et al.Journal of the National Cancer Institute|March 6, 2003
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne, Valerie Bardou, Torsten A Hopp, et al.Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 24, 2004
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation studySyed K Mohsin, Heidi Weiss, Thomas Havighurst, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2006
Molecular heterogeneity of inflammatory breast cancer: a hyperproliferative phenotypeDang M Nguyen, Kathy Sam, Anna Tsimelzon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2002
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignanciesLillian L Siu, Eric K Rowinsky, Lisa A Hammond, et al.Pageof 4